Will you incorporate immunotherapy in neoadjuvant treatment of triple negative breast cancer based off KEYNOTE-522?

Based on pCR and EFS data from KEYNOTE 522 and recent FDA approval?

Answer from: Medical Oncologist at Community Practice

Insurance issues aside, I would incorporate immunotherapy into neoadjuvant triple negative therapy. I participated in this trial and I am aware of the pathologic complete response data. I suspect that this could lead, ultimately, to FDA approval. In the meantime, if feasible, I would use the Keynote...

Comments

Medical Oncologist at Saint Barnabas Medical Center
Is the protocol published? I cant find how much de...

Medical Oncologist at NYU Langone Medical Center
For a young pre-menopause patient treated with NAC...

Medical Oncologist at Crystal Run Healthcare
I have the same scenario, I was wondering the same...

Answer from: Medical Oncologist at Academic Institution

Yes. T2 or greater. Questions remain: is carboplatin truly necessary for all patients? Do patients who achieve pCR need adjuvant pembrolizumab?

Please select the option that best describes you:

Will you incorporate immunotherapy in neoadjuvant treatment of triple negative breast cancer based off KEYNOTE-522?

Related Questions